Pabst’s patent, entitled “Analog Data Generating and Processing Device Having a Multi-Use Automatic Processor,” issued in 2015 and claims priority to a 1999 application through continuations of applications that issued as Pabst’s 399 and 449 patents. That same specification also gave rise to Papst’s 144 and 746 patents. The specification describes an interface device for communication between a data device (on one side of the interface) and a host computer (on the other). The interface device achieves high data transfer rates, without the need for a user-installed driver specific to the interface device, by using fast drivers that are already standard on the host computer for data transfer, such as a hard-drive driver. The interface device signals to the host device that the interface device is an input/output device for which the host already has such a driver. On inter partes review, Patent Trial and Appeal Board determined that claims 1– 38 and 43–45 are unpatentable for obviousness based on a combination of the Aytac patent, a publication setting forth standards for the Small Computer System Interface-2, and “admitted prior art.” The Federal Circuit affirmed, finding that Pabst’s arguments are barred by issue preclusion and fail on the merits. View "Pabst Licensing GMBH & Co. KG v. Samsung Electronics America, Inc." on Justia Law

Guitar Center, which sells musical instruments, created a new brand of woodwind and brass instruments produced by Eastman, “Ventus.” Barrington owns the trademark “Vento,” which is used in relation to instruments it sells. Barrington began using its mark in commerce in 2009 and achieved gross sales just under $700,000. Barrington filed for registration of its “Vento” mark in January 2010. In March 2011, Guitar Center began selling instruments using the “Ventus” mark, with gross sales totaling about $5 million. Barrington filed suit against Eastman, Music & Arts, Guitar Center, and Woodwind. A jury found that only Guitar Center's sales infringed and awarded Barrington the total amount of Guitar Center sales—$3,228. Barrington later discovered that Music & Arts and Woodwind were divisions of Guitar Center. Barrington moved the court to amend the damages award to $4,947,200, the total sales for the “Ventus” mark by all of the Guitar Center owned stores. The district court denied the Rule 59(e) motion. The Seventh Circuit affirmed. Barrington gave no reason to conclude that the jury’s verdict would be different if it were aware Music & Arts and Woodwind were merely divisions of Guitar Center; it found Music & Arts and Woodwind did not infringe on the “Ventus” mark and there was no basis to award Barrington their “Ventus” related sales. View "Barrington Music Products, Inc v. Music & Arts Center" on Justia Law

This consolidated appeal stemmed from the trusts' motion for a temporary restraining order and preliminary injunction enjoining the use of Phyllis Schafly's intellectual property. The Eighth Circuit affirmed the denial of preliminary injunctive relief under 28 U.S.C. 1292(a)(1) and held that the trusts would not be entitled to the traditional presumption of irreparable harm in trademark cases because they did not promptly seek preliminary injunctive relief concerning the trademark infringement, regardless of whether the presumption survived recent Supreme Court decisions emphasizing the movant's burden to show that irreparable injury was likely in the absence of an injunction. The court dismissed the appeal of the order staying litigation for lack of appellate jurisdiction, because the order was temporary and did not effectively end the litigation. View "Phyllis Schlafly Revocable Trust v. Cori" on Justia Law

Sony’s patent is directed to “an information recording medium” (e.g., a compact disk, video disk, or magneto-optical disk) that can store audio data having multiple channels and “a reproducing device” that can select which channel to play based on a default code or value stored in nonvolatile memory. The specification states that the reproducing device is provided with “storing means” for storing the audio information (e.g., audio data recorded in different languages), “reading means” for reading codes associated with the audio information (e.g., 0, 1, 2, and 3 for English, French, German, and Japanese, respectively), and “reproducing means” for reproducing the audio information based on the default code or value. The specification gives the example of a device manufactured to record and store audio data (e.g., of a movie) in multiple different languages for various countries. On inter partes review, the Patent Trial and Appeal Board found two claims unpatentable as obvious. The Federal Circuit vacated. The Board erred in construing the “reproducing means” limitation, which is more appropriately construed as computer-implemented, and that the corresponding structure is a synthesizer and controller that performs the algorithm disclosed in the specification. View "Sony Corp. v. Iancu" on Justia Law

Quest’s patent relates to a system for displaying inspection data collected from certain commercial furnaces (e.g., a furnace used in a refinery). The patent attempts to improve upon how prior art systems displayed collected inspection data, but does not purport to improve upon how inspection data is collected or the type of data collected; the system comprises “a storage device for storing the inspection data collected by an inspection tool flushed through the furnace” and a computer programmed to generate a plurality of data markers in relation to that data, partition the data at the data markers, and generate a display of the partitioned inspection data, “wherein the display is a two-dimensional or three-dimensional representation of one or more of the tube segments of the furnace.” On summary judgment, the district court held that five claims of the patent were invalid under 35 U.S.C. 102(b) because the claimed invention was offered for sale more than one year before the filing of the patent application. The Federal Circuit held that the district court properly construed the claims and that three claims are invalid based on that construction but that the court erred in disregarding declarations of the inventors under the sham affidavit doctrine, and that Quest raised a genuine issue of material fact as to the validity of two claims. View "Quest Integrity USA, LLC v. Cokebusters USA Inc." on Justia Law

PlayNation filed suit against Velez for trademark infringement over the use of the Gorilla Gym mark and the district court entered judgment for PlayNation. The Eleventh Circuit held that the district court did not clearly err in holding that Velez infringed on PlayNation's trademark, and in cancelling Velex's trademark registration on that basis. However, the district court abused its discretion in holding that PlayNation was entitled to an accounting of Velex's profits due to willful infringement based solely on Velex's continued lawful use of its mark after Velex was served with the complaint. Therefore, the court affirmed in part, vacated in part, and remanded in part. View "PlayNation Play Systems, Inc. v. Velex Corp." on Justia Law

Tempnology licensed Mission to use Tempnology’s trademarks in connection with the distribution of clothing. Tempnology filed for Chapter 11 bankruptcy and sought to reject its agreement with Mission as an “executory contract” under 11 U.S.C. 365, which provides that rejection “constitutes a breach of such contract.” The Bankruptcy Court approved Tempnology’s rejection, holding that the rejection terminated Mission’s rights to use Tempnology’s trademarks. The Bankruptcy Appellate Panel reversed, holding that rejection does not terminate rights that would survive a breach of contract outside bankruptcy. The First Circuit reinstated the Bankruptcy Court’s decision. The Supreme Court reversed, first holding that the case is not moot. Mission presented a plausible claim for damages, sufficient to preserve a live controversy. A debtor’s rejection of an executory contract under Bankruptcy Code Section 365 has the same effect as a breach of that contract outside bankruptcy and cannot rescind rights that the contract previously granted. A licensor’s breach cannot revoke continuing rights given under a contract (assuming no special contract term or state law) outside of bankruptcy; the same result follows from rejection in bankruptcy. Section 365 reflects the general bankruptcy rule that the estate cannot possess anything more than the debtor did outside bankruptcy. The distinctive features of trademarks do not mandate a different result. In delineating the burdens a debtor may and may not escape, Section 365’s edict that rejection is breach expresses a more complex set of aims than facilitating reorganization. View "Mission Product Holdings, Inc. v. Tempnology, LLC" on Justia Law

Leonel Romero-Ochoa was convicted by jury of burglary, unlawful imprisonment, assault, and multiple counts of rap all arising from an incident in which he broke into a woman's home, beat her, and raped her twice. At trial, Romero-Ochoa wanted to admit evidence that the victim was a U-visa applicant, which would grant her temporary legal resident status if she was the victim of a qualifying crime and helps law enforcement investigate or prosecute that crime. The trial court excluded the U-visa evidence. Romero-Ochoa argued that exclusion violated his constitutional rights to present a defense and confront witnesses. The Court of Appeals agreed and revered all but the unlawful imprisonment conviction, holding the constitutional error was harmless beyond a reasonable doubt as to that conviction but not the others. The Washington Supreme Court granted the State's petition for review, which raised only the harmless error issue. The Supreme Court reversed, finding any error excluding the U-visa evidence was harmless as to all of Romero-Ochoa's convictions. The convictions were reinstated, and the matter remanded to the Court of Appeals to consider the claim of sentencing error that was not previously reached. View "Washington v. Romero-Ochoa" on Justia Law

Non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin and naproxen, control pain but have undesirable side effects, including gastrointestinal problem. Some practitioners began prescribing acid inhibitors, including PPIs, to reduce the acidity in the gastrointestinal tract. The combination therapy had complications. Stomach acid degraded the PPI before it could reach the small intestine. To address those complications, Dr. Plachetka invented a drug (Vimovo®.) that coordinated the release of an acid inhibitor and an NSAID in a single tablet with a core of an NSAID, an enteric coating around the NSAID that prevents its release before the pH increases to a certain desired level, and an acid inhibitor like PPI around the outside of the enteric coating that actively works to increase the pH to the desired level. Plachetka’s invention contemplates using some uncoated PPI for immediate release. Manufacturers, wanting to market a generic version of Vimovo®, submitted Abbreviated New Drug Applications to the FDA. They stipulated to infringement, except with respect to one ANDA product and alleged that the Vimovo® patents were invalid as obvious over prior art, 35 U.S.C. 103 and for lack of enablement and adequate written description, 35 U.S.C. 112. The Federal Circuit reversed a holding that the Vimovo® patents were valid. The specification provides nothing more than a claim that uncoated PPI might work, even though persons of ordinary skill in the art would not have thought so, and does not satisfy the written description requirement. View "Nuvo Pharmaceuticals, Inc. v. Dr. Reddy's Laboratories Inc." on Justia Law

BTG’s 438 Patent, entitled “Methods and Compositions for Treating Cancer,” discloses the administration of a therapeutically effective amount of a CYP17 inhibitor, such as abiraterone acetate, in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. The patent defines an “anti-cancer agent” as “any therapeutic agent that directly or indirectly kills cancer cells or directly or indirectly prohibits[,] stops[,] or reduces the proliferation of cancer cells.” BTG sued Amneal, asserting that its Abbreviated New Drug Applications (ANDA) for the generic version of BTG’s abiraterone product ZYTIGA® infringed the patent. On inter partes review, the Patent Trial and Appeal Board found that the patent’s claims would have been obvious under 35 U.S.C. 103. The district court affirmed, accepting the Board’s claim construction and the same combination of prior art. The Federal Circuit affirmed. The Board correctly concluded that the claims cover a therapy in which abiraterone has an anticancer effect, while prednisone either has its own anti-cancer effect or has a palliative/side-effect reduction effect, and that the “prior art provides a reasonable expectation that prednisone could be used as a therapeutic agent in the treatment of prostate cancer.” View "BTG International Ltd. v. Amneal Pharmaceuticals LLC" on Justia Law